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Inﬂuenza is a transmissible viral pathogen that continues to cause substantial morbidity and mortality. Osel-
tamivir is an orally administered antiviral medication that selectively inhibits the inﬂuenza neuraminidase
enzymes that are essential for viral replication. Treatment of infected children  1 year and adults of all ages
may decrease the severity and duration of the symptoms of infection, while prophylactic dosing can prevent
their onset. Oseltamivir is ingested in the form of a prodrug (oseltamivir phosphate) that is rapidly converted
by hepatic esterases into the active metabolite, oseltamivir carboxylate. Oseltamivir carboxylate has high bio-
availability and penetrates sites of infection at concentrations that are sufﬁcient to inhibit viral replication. The
pharmacokinetics of oseltamivir and oseltamivir carboxylate are dose proportional after repeated doses of up
to 500 mg twice daily. This predictable proﬁle means that oseltamivir is suitable for use in diverse patient popu-
lations, which may include young children and elderly patients, various ethnic groups and those with renal or
hepatic impairment. As the potential for drug interactions is low, oseltamivir is also suitable for use in patients
with co-morbid conditions who are likely to be receiving concomitant medications.
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Introduction
Inﬂuenza is an infectious viral agent that continues to cause
considerable morbidity and mortality.
1 The pathogenicity of the
inﬂuenza virus is now well understood, and this has led to the
development of a range of antiviral agents for the treatment
and prevention of its debilitating symptoms.
2 Oseltamivir (Tami-
ﬂu
w; F. Hoffmann-La Roche Ltd) is an orally administered antiviral
for the management of inﬂuenza A and B infections in children
 1 year and adults of all ages.
3 It is a widely used medication,
with global experience now exceeding 65 million treatment
courses. For therapeutic use, oseltamivir is taken as a twice-daily
regimen for 5 consecutive days, while for prophylaxis it is taken
on a once-daily schedule for up to 42 days.
3 Adults take oselta-
mivir at a standard dose of 75 mg, while children receive unit
doses that are selected on the basis of body weight.
3 Oral
capsule (35, 40 and 75 mg) and suspension formulations are
now readily available.
3
Oseltamivir is ingested in the form of an oral prodrug (oselta-
mivir phosphate; OP) that is rapidly metabolized to the active
form, oseltamivir carboxylate (OC) (Figure 1).
4 In infected
patients, OC binds to and inhibits the active site of the neurami-
nidase enzymes that are present on all inﬂuenza viruses and are
essential for the release of progeny virions from infected host
cells (Figure 2).
2 In this way, OC can reduce viral replication,
which in turn can limit the viral load and course of infection in
the host. When started within 48 h of the onset of illness, this
action can limit the severity and duration of the symptoms of
inﬂuenza and the risk of associated complications, such as bron-
chitis, pneumonia and otitis media.
2 Symptomatic illness can
also be prevented with prophylactic administrations.
2
Since the active site of the neuraminidase enzyme is highly
conserved, oseltamivir has activity against all of the neuramini-
dase subtypes so far tested in vitro.
5 These include the neuramini-
dases of human seasonal viruses, avian viruses and pandemic
viruses,
5 including the newly emergent pandemic (H1N1) 2009
virus.
6 A variety of laboratory strains and clinical isolates have
shown susceptibility to OC, with 50% inhibitory concentrations
(IC50s) ranging from 0.01 to 69.2 nM, depending on the inﬂuenza
strain (Table 1).
5,7–9 To place this in context, the average
minimum plasma concentration of OC achieved with the twice-
daily treatment regimen at the standard 75 mg dose is
330 nM.
4 Importantly, OC is highly selective for inﬂuenza neura-
minidase,andshowslittleornoactivityagainstneuraminidasesof
other viruses, bacteria or human liver microsomes.
10
Pharmacokinetics of oseltamivir and OC
To effectively limit viral replication and the viral load, therapeutic
concentrations of OC must be achieved at all sites of infection
and maintained for the duration of the dosing interval. For this
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ii5reason, the pharmacokinetic proﬁles of oseltamivir and OC have
been extensively studied in healthy volunteers and infected
patients. Inter- and intra-subject variability across different
demographic populations has also been widely investigated.
Absorption, distribution, metabolism and elimination
Following oral administration of OP, oseltamivir is rapidly
absorbed from the gastrointestinal tract and converted by
hepatic esterases into the active metabolite OC, giving an
absolute bioavailability of 80%.
4,11 OC is detectable in plasma
within 30 min of dosing, and concentrations reach near-maximal
levels after 3–4 h, exceeding oseltamivir concentrations by
.20-fold.
4,11 OC plasma concentrations display minimal inter-
and intra-subject variability, and concomitant food intake has
little effect on bioavailability.
4,11The absorption rate of oseltami-
vir is unaffected under conditions of altered gastric pH, such as
that induced by cimetidine and antacids.
4,11
The volume of distribution of OC after intravenous adminis-
tration in man is 23–26 L.
4,11 This value is similar to the extra-
cellular volume of body water in humans, suggesting that the
metabolite may penetrate infection sites at concentrations
similar to those in plasma. Indeed, oseltamivir and OC are sys-
temically distributed, with therapeutic concentrations attained
in the lung, trachea and nasal mucosa,
4 as well as the sinuses
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ii6and middle ear (Figure 3).
12 Eisenberg et al.
13 also conﬁrmed
that OC reached the lung following oral dosing in rats, and was
detected in the bronchoalveolar lining ﬂuid with equal or
greater exposure to that in plasma and a slower clearance.
At least 75% of an oral dose of the prodrug is converted into
OC by ﬁrst-pass metabolism, and ,5% is recovered in urine as
OP.
4,11 Neither oseltamivir nor OC interacts with human cyto-
chrome P450 mixed-function oxidases or glucuronyl transferases
in vitro. OP and OC are eliminated primarily by renal excretion,
but small amounts (,20% of the oral dose) of both compounds
are also eliminated in faeces.
4 Following oral dosing, plasma con-
centrations of oseltamivir decline rapidly (apparent elimination
half-life of 1–3 h), while OC concentrations persist for longer
(apparent elimination half-life of 6–10 h), permitting twice-daily
dosing. Renal clearance of both compounds exceeds the glomer-
ular ﬁltration rate, indicating that renal tubular secretion contrib-
utes to elimination; for OC, this has been shown to proceed via
the anionic transport process.
4,11
Oseltamivir has shown a high safety margin in acute, sub-
acute and chronic toxicity studies.
4 The pharmacokinetics of
oseltamivir are linear and dose proportional at doses of up to
500 mg twice daily.
4,11 Only modest accumulation (,2-fold) of
OC is noted prior to attainment of steady state. The pharmaco-
kinetics of multiple dose administration can be predicted from
those of single dosing and provide no indication of a temporal
change in the disposition of either oseltamivir or OC.
Steady-state plasma concentrations of OC are achieved within
2–3 days of twice-daily administration.
4,11 Recently, the phar-
macokinetics of high doses of oseltamivir have been examined
in healthy Thai volunteers.
14 In a dose-escalation study, 21 indi-
viduals received single doses of oseltamivir at four increasing
dose levels, giving a total of 125 individual series. Doses of up
to 675 mg were well tolerated. Pharmacokinetics were dose-
linear, with rapid absorption and conversion (median¼93%)
into OC. Median [95% conﬁdence interval (CI)] elimination
half-lives were 1.0 (0.9–1.1) h for oseltamivir and 5.1 (4.7–5.7)
h for OC. One subject repeatedly showed markedly reduced
conversion of oseltamivir into OC due to constitutionally impaired
carboxylesterase activity.
14
Inﬂuence of patient demographics and ethnicity
Overall, there are no clinically relevant differences in the pharma-
cokinetics of oseltamivir or OC between healthy volunteers and
infected patients; this applies in adults of different sexes, ages
and weights.
11 Equally, ethnicity does not appear to affect the
pharmacokinetics of the prodrug or active metabolite. In a
study in which healthy Japanese and Caucasian subjects were
randomized to 75 or 150 mg of oseltamivir or placebo twice
daily for 6 days, with a single dose on day 7, individual and
mean pharmacokinetics of oseltamivir and OC were similar
between the two groups (Figure 4).
15 Ethnic differences produced
no observable effect on individual exposures at steady state.
Although a prospective comparison has not been performed in
children, data from four separate studies involving 141 Cauca-
sian and 18 Japanese children have been pooled to compare
plasma concentrations.
16 After normalization to a 2 mg/kg
dose, interquartile ranges for oseltamivir concentration were
3.63–26.75 ng/mL (Caucasian) and 3.95–22.05 ng/mL (Japa-
nese). Results for OC were very similar.
Inﬂuence of renal or hepatic impairment
Exposure to OC is increased as a result of decreased renal func-
tion, and severe renal insufﬁciency (creatinine clearance rates of
,30 mL/min) is associated with a marked increase in
exposure.
4,17 In this patient group, a reduced treatment dose
of 75 mg once daily is recommended.
3 Oseltamivir is not rec-
ommended for patients with end-stage renal disease (creatinine
clearance ,10 mL/min).
3 In vitro experiments indicate that the
metabolic pathway of oseltamivir conversion into OC in the
liver is unlikely to be appreciably altered in subjects with moder-
ate hepatic impairment.
18 This has been conﬁrmed in a clinical
study, and no dose adjustment is recommended for patients
with mild to moderate hepatic impairment.
11
Inﬂuence of age
Exposure to oseltamivir in elderly patients increases in proportion
to the usual age-related decline in renal function.
4,11,19 However,
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Figure 3. Concentration–time curves for oseltamivir carboxylate in
plasma, middle ear and sinuses after ﬁve twice-daily doses of 75 mg of
oseltamivir (n¼24). Reproduced from Kurowski et al.
12 with permission.
Table 1. Inhibitory concentrations (IC50s) of oseltamivir carboxylate
against different neuraminidase subtypes in vitro
5,7–9
Virus subtype IC50 (nM) Virus subtype IC50 (nM)
H1N1 0.7
8–2.2
8 H6N5 33.2
9
H1N9 0.3
5 H7N2 2.7
9
H2N2 0.3
5–9.0
7 H7N7 4.4
9
H2N3 0.01
8–3.3
9 H8N4 0.4
5–47.0
9
H3N2 0.2
8–0.6
8 H9N2 1.9
9–15.0
7
H3N8 0.8
5 H10N7 0.8
5–8.2
9
H4N6 0.4
5–3.2
9 H10N8 29.7
9
H4N8 69.2
9 H11N9 9.5
9–17.7
9
H5N1 7.0
7 H12N5 1.5
5
H5N3 2.9
9 H13N6 4.9
9
H6N1 36.1
9 H14N5 36.8
9
H6N2 0.84
8 B 1.7
5–24.3
8
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JACas this increase is small relative to the known safety margin, no
dose adjustment is necessary. There are no clinically relevant
differences in the pharmacokinetics of oseltamivir or OC
between healthy children and infected children.
20 Clearance of
OC increases with increasing body weight, and hence age, and
this is particularly apparent when the OC clearance is expressed
per kg of body weight. The OC rate of clearance per kg of body
weight in children decreases with advancing age, such that
exposure in children  13 years is similar to that in adults.
20
Although the range of exposures in children and adolescents
 16 years following a 2 mg/kg oseltamivir dose was within the
range that was safe and effective in adults receiving 75 or
150 mg doses twice daily, there was a clear trend towards
higher systemic clearance per kg of body weight in younger chil-
dren. Administration of 2 mg/kg to children in the age range 3–
16 years demonstrated a signiﬁcant downward trend with
decreasing age (Figure 5). Therefore, a simple age- and weight-
based unit dosing algorithm was developed to ensure exposures
in children comparable to those in adults.
3 The algorithm is
based on atargetexposurewindowand a simple linear regression
analysis of pharmacokinetic data from children and adolescents
following a single 2 mg/kg dose of oseltamivir. The algorithm
was shown to maintain drug exposure within the target efﬁcacy/
safety window, while also allowing for a convenient dose
regimen.
20
Drug interactions
Patients with inﬂuenza often take over-the-counter medications
to ease their symptoms. In addition, many patients with
co-morbidities receive concomitant drugs. Drug interactions could
adversely affect the pharmacokinetics of the co-administered
medications, and thus their efﬁcacy and safety. With this in mind,
thepotentialforclinicallyrelevantinteractionsbetweenoseltamivir
and OC and a variety of commonly used medications has been
widely studied.
Oseltamivir has limited potential for clinically relevant inter-
actions with commonly co-administered drugs. When oseltamivir
was taken with paracetamol (acetaminophen), plasma concen-
trations of OC and paracetamol remained unaffected.
4 Equally,
co-administration of aspirin
21 or antacids
22 with oseltamivir had
no relevant effect on the pharmacokinetics of these compounds.
Further studies indicated that neither cimetidine nor amoxicillin
exhibited any interaction with oseltamivir.
23 Furthermore, the
latter investigation conﬁrmed that oseltamivir is a weak competi-
tor for the anionic renal tubular secretion processes and that its
potential to compete effectively with other organic acids that
undergo renal tubular secretion is minimal.
23 Care should be
taken with medications with a narrow therapeutic margin that
are co-excreted, e.g. methotrexate. In renal transplant patients,
co-administration of oseltamivir was shown not to change the
pharmacokinetics of the immunosuppressant drugs cyclosporin,
mycophenolate mofetil and tacrolimus, and the
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Figure 5. Area under the plasma concentration–time curve (AUC) for
oseltamivir carboxylate in children aged 3–16 years administered
2 mg/kg oseltamivir (two pooled studies). The broken line represents
the regression line for the open circles (study 1) and the continuous
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Reproduced from Oo et al.
20 with permission.
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7 days of treatment with oseltamivir in healthy Caucasian and
Japanese adult volunteers. Reproduced from Schentag et al.
15 with
permission.
Davies
ii8pharmacokinetics of oseltamivir itself in these patients were
found to be similar to those in patients with native kidneys.
24
Severalgroupshavestudiedtheco-administrationofoseltami-
vir and probenecid.
14,25,26 The ability of probenecid to modify the
renal secretion of other drugs has previously been exploited, and
its use as a ‘sparing agent’ to extend oseltamivir supplies in the
event of an inﬂuenza pandemic has been suggested.
27,28 In one
study, co-administration of oseltamivir and probenecid resulted
in an increase of 2.5-fold in exposure to OC, indicating that
tubular secretion of the latter proceeds via the anionic
pathway.
23 Although this pathway is shared by some other
drugs, clinically relevant interactions are unlikely. A more recent
investigation found a mean decrease in the apparent volume of
OC distribution of 40% (95% CI, 37%–44%) and mean reduction
in renal elimination of 61% (58%–62%), resulting in an increase
in the median AUC for OC of 154% (range, 71%–278%).
14
Two groups have recently investigated the pharmacokinetics
of oseltamivir/probenecid combinations in more detail.
25,26 In
the ﬁrst of these, Holodniy et al.
25 compared the pharmacoki-
netics of the combination (oseltamivir 75 mg once every 48 h
plus probenecid 500 mg four times a day) with oseltamivir
alone (75 mg once daily). Oral clearance of OC was found to
be 25% lower with the combination, and 48 h plasma exposure
results showed a lack of bioequivalence. However, the mean
trough concentrations of OC at the end of a dosing interval in
the two groups were not signiﬁcantly different, suggesting that
co-administration of probenecid might allow reduction of oselta-
mivir dose without compromising neuraminidase inhibition.
25 In
the second study, Rayner et al.
26 used a population pharmacoki-
netic model to simulate combination regimens of oral oseltami-
vir (45 and 30 mg twice daily) and oral probenecid (500 mg/6
hourly). Probenecid plus 45 mg of oseltamivir achieved all the
pharmacokinetic parameters expected of oseltamivir alone, but
combination with 30 mg of oseltamivir and dose interval exten-
sion approaches did not.
26 It is noteworthy, however, that unsui-
table oseltamivir/probenecid regimens, or non-compliance with
suitable regimens, could increase the risk of emergence of resist-
ant virus via suboptimal dosing. Moreover, co-administration
could compromise the systemic distribution of OC, which could
be vital in cases of infection with highly pathogenic virus. Along-
side the potential for multiple, clinically relevant drug inter-
actions and adverse events with probenecid, the utility of the
combination strategy appears to be limited.
26
Oseltamivir has not previously been associated with haemato-
logical adverse reactions or interference with the coagulation
process. However, following sporadic post-marketing reports of
bleeding in patients on anticoagulant therapy, the pharmacoki-
netic interaction between the agents was re-evaluated in 20
patients receiving daily warfarin and with international normal-
ized ratio (INR) values of 2.0–3.5 during the previous 2 weeks.
29
Thesevolunteerswererandomizedtotwice-daily75 mgofoselta-
mivir for 4 days with a single 75 mg dose on day 5, or warfarin
alone in a two-way crossover design separated by a wash-out of
4–8 days. Anticoagulant effects were assessed by calculating
overall change (AUEC0–96) and maximum absolute change from
baseline (Emax) in INR and Factor VIIa, and change in vitamin K1
concentrations. For both treatments, changes from baseline in
INR and Factor VIIa during treatment were small and there
were also no statistically signiﬁcant differences between treat-
ments in mean Emax for INR and Factor VIIa, or in the change
from baseline in vitamin K1 concentration. Oseltamivir did not
alter warfarin pharmacokinetics. Oseltamivir was well tolerated
in this population, with no adverse safety ﬁndings.
29
Conclusions
Oseltamivir is an orally administered antiviral for the treatment
and prophylaxis of inﬂuenza A and B infections in adults and chil-
dren aged  1 year. After dosing, the prodrug (OP) is readily
absorbed from the gastrointestinal tract and rapidly converted
into the active metabolite, OC. In all patient groups, OC has
high bioavailability and is systemically distributed to infection
sites at concentrations sufﬁcient to inhibit a range of inﬂuenza
virus neuraminidases. Oseltamivir has a predictable linear phar-
macokinetic proﬁle and is suitable for a variety of patient popu-
lations and age groups. The potential for clinically relevant drug
interactions is low. These characteristics underpin the use of
oseltamivir in the diverse patient populations that are likely to
be affected by seasonal and pandemic inﬂuenza viruses.
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